Oliver Cornely to Pyridines
This is a "connection" page, showing publications Oliver Cornely has written about Pyridines.
Connection Strength
2.034
-
Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018 Aug; 61(8):518-533.
Score: 0.472
-
Isavuconazole shortens the QTc interval. Mycoses. 2018 Apr; 61(4):256-260.
Score: 0.454
-
Isavuconazole: is there a need for a new antifungal? J Antimicrob Chemother. 2017 03 01; 72(suppl_1):i2-i4.
Score: 0.428
-
Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol. 2020 Jun 01; 58(4):417-424.
Score: 0.134
-
Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. Mycoses. 2018 Nov; 61(11):868-876.
Score: 0.118
-
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses. 2018 Jul; 61(7):485-497.
Score: 0.116
-
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. Mycoses. 2018 Jul; 61(7):420-429.
Score: 0.116
-
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016 Jul; 16(7):828-837.
Score: 0.100
-
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021 06; 21(6):e149-e162.
Score: 0.035
-
COVID-19 associated pulmonary aspergillosis. Mycoses. 2020 Jun; 63(6):528-534.
Score: 0.033
-
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. J Antimicrob Chemother. 2018 03 01; 73(3):757-763.
Score: 0.029